Adults 18 to 75, any sex, with Nonalcoholic Steatohepatitis or Liver Cirrhosis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Participants With Treatment-emergent Adverse Events (AE)Primary· Day 1 until the study was terminated (up to approximately 4 years)
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. A treatment-emergent AE is an AE that occurs after a participant receives study drug.
Group
Value
95% CI
Cenicriviroc (CVC) 150 mg
140
Adverse events — posted to ClinicalTrials.gov
Time frame: Day 1 until the study was terminated (Up to approximately 4 years).
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Cenicriviroc (CVC) 150 mg
Serious: 40/167 (24%)
Deaths: 1/167
Serious adverse events (58 terms)
Reaction
System
Cenicriviroc (CVC) 150 mg
Angina pectoris
Cardiac disorders
—
Cellulitis
Infections and infestations
—
Dehydration
Metabolism and nutrition disorders
—
Acute kidney injury
Renal and urinary disorders
—
Cholecystitis acute
Hepatobiliary disorders
—
Pneumonia legionella
Infections and infestations
—
Sepsis
Infections and infestations
—
Basal cell carcinoma
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
—
Bowen's disease
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
This rollover study will provide open-label treatment with cenicriviroc and will assess the long-term safety of continued treatment with cenicriviroc in participants who participated in either the CENTAUR study 652-2-203 \[NCT02217475\] or the AURORA study \[NCT03028740\].
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT04488081 — I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
· Phase 2
· active not recruiting
NCT03376841 — Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites
· Phase 1
· completed
NCT03028740 — AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Non
· Phase 3
· terminated
NCT02684799 — Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination
· Phase 1
· completed
NCT02217475 — Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants
· Phase 2
· completed
Other recruiting trials for Nonalcoholic Steatohepatitis
Currently open trials in the same condition.
NCT07481734 — Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)
· Phase 2
· recruiting
NCT06465186 — A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
· Phase 2
· active not recruiting
NCT05526144 — Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans
· Phase 2
· recruiting
NCT05330923 — Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease
· recruiting
NCT04550481 — Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
· Phase 2
· active not recruiting
Other Tobira Therapeutics, Inc. trials
Trials by the same sponsor.
NCT03028740 — AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Non
· Phase 3
· terminated
NCT02653625 — PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis
· Phase 2
· completed
NCT02684799 — Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination
· Phase 1
· completed
NCT02685462 — Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin
· Phase 1
· completed
NCT02330549 — ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) an
· Phase 2
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tobira Therapeutics, Inc.
Last refreshed: 2 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03059446.